Biological E, a pharmaceutical and biologics company, completed the acquisition of Akorn India, a producer of vaccines and injectable medicines, from pharmaceutical companies Akorn and WorldAkorn. Financial terms were not disclosed. “We are happy to have made a strategic investment in acquiring Akorn India. We would leverage BE’s and Akorn India’s capabilities to enhance our supply capacities both in Vaccines and in Generic Injectables. The timing of this acquisition is fortuitous as it will immediately allow us to expand our capacity to manufacture our investigational Covid-19 vaccine. With these capacities, we would be in a position to offer over 1bn doses per annum,” Mahima Datla, Biological E. Managing Director.